logo
Two Galaxies in 'joust' before mega-merger

Two Galaxies in 'joust' before mega-merger

Korea Herald22-05-2025
WASHINGTON (Reuters) — Astronomers have observed two distant galaxies — both possessing roughly as many stars as our Milky Way — careening toward each other before their inevitable merger at a time when the universe was about a fifth its current age, a scene resembling two knights charging in a joust.
The galaxies, observed using two Chile-based telescopes, were seen as they existed about 11.4 billion years ago, approximately 2.4 billion years after the Big Bang event that initiated the universe.
At the heart of one of the galaxies resides a quasar, a highly luminous object powered by gas and other material falling into a supermassive black hole. The intense radiation across the electromagnetic spectrum unleashed by the quasar is seen disrupting clouds of gas and dust, known as molecular clouds, in the other galaxy.
It is molecular clouds that give rise to stars. But the effects of the quasar's radiation turned the clouds in the affected region into "only tiny dense cloudlets that are too small to form stars," said astrophysicist Sergei Balashev of the Ioffe Institute in Saint Petersburg, Russia, co-lead author of the study published on Wednesday in the journal Nature.
This is the first time such a phenomenon has been observed, Balashev said.
Stars form by the slow contraction under gravity of these clouds, with small centers taking shape that heat up and become new stars. But the galaxy affected by the quasar's radiation was left with fewer regions that could serve as such stellar nurseries, undermining its star formation rate.
The interaction between the two galaxies reminded the researchers of a medieval joust.
"Much like jousting knights charging toward one another, these galaxies are rapidly approaching. One of them — the quasar host — emits a powerful beam of radiation that pierces the companion galaxy, like a lance. This radiation 'wounds' its 'opponent' as it disrupts the gas," said astronomer and co-lead author Pasquier Noterdaeme of the Paris Institute of Astrophysics in France.
Supermassive black holes are found at the heart of many galaxies, including the Milky Way. The researchers estimated the mass of the one that serves as the engine of the quasar studied in this research at about 200 million times that of our sun.
The intense gravitational strength of the supermassive black hole pulls gas and other material toward it. As this stuff spirals inward at high speed, it heats up due to friction, forming a disk that emits extremely powerful radiation in two opposite directions, called biconical beams.
The ultraviolet light from one of these beams is what played havoc with the gas in the companion galaxy.
This supermassive black hole is much more massive than the one at the center of the Milky Way — called Sagittarius A*, or Sgr A* — which possesses roughly 4 million times the mass of the sun and is located about 26,000 light-years from Earth. A light-year is the distance light travels in a year, 9.5 trillion kilometers.
The researchers used the Atacama Large Millimeter/submillimeter Array, or ALMA, to characterize the two galaxies and used the European Southern Observatory's Very Large Telescope, or VLT, to probe the quasar as well as the gas in the companion galaxy.
The configuration of the galaxies as viewed from the perspective of Earth enabled the researchers to observe the radiation from the quasar passing directly through the companion galaxy.
Most galactic mergers that have been observed by astronomers occurred later in the history of the universe.
"Galaxies are typically found in groups, and gravitational interactions naturally lead to mergers over cosmic time," Noterdaeme said. "In line with current understanding, these two galaxies will eventually coalesce into a single larger galaxy. The quasar will fade as it exhausts the available fuel."
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application
iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application

Korea Herald

time05-08-2025

  • Korea Herald

iNtRON Bio, Demonstrated Toxin-Neutralizing Effect of IMPA™ Phage Engineering Technology in Colorectal Cancer Model and Completed the US Patent Application

• Successful validation of payloaded anti-colibactin toxin phage using IMPA ™ technology • Demonstrated ' Dual-target Therapeutic Strategy ' by bacterial eradication and toxin neutralization • Filed the US patent application for the candidate substance and preclinical studies including PoC underway BOSTON and SEOUL, South Korea, Aug. 5, 2025 /PRNewswire/ -- Recently, a specific genotype of E. coli that may cause colorectal cancer has been detected in commonly eaten leafy vegetables such as lettuce, raising consumer concerns. Among these strains, pks+ E. coli is of particular concern. This bacterium produces a toxic substance in the intestine that causes DNA damage (ICLs, Interstrand Cross-Links), which leads to DSBs (Double Strand Breaks), and has been shown in numerous studies, including Nature (2023), to increase the risk of colorectal cancer over time. Amid this situation, as an innovative bacteriophage technology development company, iNtRON Bio proposes a new possibility for microbiome-based anticancer drugs in treating colorectal cancer—considered a hard-to-treat disease—by applying our phage engineering technology called IMPA™. iNtRON Bio has been developing PHAGERIA Ⓡ, an immunotherapeutic targeting gut bacteria, and through the IMPA™ phage engineering technology developed in-house, iNtRON Bio has secured a new drug candidate payloaded with a substance that effectively eliminates colibactin ,a major causative agent of colorectal cancer and have filed a related US patent application. The phage engineering technology IMPA™ (Intelligent Modular Phage Assembly) was formerly known as the "robot bacteriophage." With the recent US patent application, it was named to clearly reflect the function as a technology for engineering modular phages (mock-up phages) that can carry therapeutic payloads. This achievement is the result of combining transposon mutagenesis, CRISPR/Cas-based forward/reverse genetics, and AI-driven analysis capabilities to explore the possibility of delivering various functional payloads. In particular, it is highly significant that iNtRON Bio successfully loaded a payload targeting colibactin ,deeply involved in colorectal cancer, onto the surface of the phage and, for the first time globally, confirmed its effectiveness. In other words, iNtRON Bio has demonstrated a dual-targeting therapeutic approach that not only eliminates pks+ E. coli, which is a main cause of colorectal cancer, but also neutralizes the toxin secreted by this bacterium. This includes verifying colibactin's role in cancer development, confirming the suppressive effect of modular phage on colorectal cancer, and proving the phage's colibactin-degrading ability—resulting in successful proof-of-concept studies and related patent acquisition. Simply put, the core of this development is that a colibactin-degrading protein was applied as a payload on the phage's protein shell, known as the capsid. Like a precision-guided missile with a warhead, the engineered phage specifically infects pks+ E. coli, kills the bacteria, and at the same time removes the colibactin toxin already secreted by the bacterium using the enzyme carried in the capsid—offering a dual therapeutic effect. Recently, the field of bacteriophage engineering is gaining attention globally. IMPA™ technology is not only a unique platform technology differentiated from other companies, but also serves as strong evidence that it can function as an actual drug delivery platform beyond simple research use. It is encouraging that iNtRON Bio's research has overcome key limitations of conventional phage-based technologies, such as decreased payload activity and phage structural instability when therapeutic substances are loaded. By confirming that the payload retains its original function, iNtRON Bio has demonstrated that it has successfully overcome high technical hurdles. The engineered phages are not merely for research purposes but were selected and validated through multiple tests with real-world and human applications in mind. iNtRON Bio has applied an advanced AI-driven optimization platform technology, refined it with great care, and plan to extend its application to other development fields for ongoing innovation. This achievement is not only a remarkable advancement in phage engineering technology but will also become a driving force for discovering innovative microbiome drug candidates through integration with other phage-based platform technologies of iNtRON Bio. It will proceed smoothly with preclinical studies including proof-of-concept (PoC) testing for combination effects with existing colorectal cancer therapies. In addition, IMPA™ phage engineering technology will be applied more broadly to ADC drug development, anti-cancer agent, and vaccines, as iNtRON Bio continues to strengthen our global technological competitiveness in these fields.

LG deepens biohealth push with investment in US anticancer biotech
LG deepens biohealth push with investment in US anticancer biotech

Korea Herald

time03-08-2025

  • Korea Herald

LG deepens biohealth push with investment in US anticancer biotech

LG Group is accelerating its push into the biohealth sector by investing in Strand Therapeutics, a US-based developer of messenger RNA-based cancer therapies. LG recently participated as a Series B investor in Strand Therapeutics through its venture capital arm, LG Technology Ventures, according to industry sources on Sunday. Headquartered in Cambridge, Massachusetts, the biopharma firm was founded in 2017 by a group of synthetic biologists from the Massachusetts Institute of Technology. The firm specializes in programming cells within the body to produce precise amounts of antigens at the right time to treat cancer, autoimmune conditions and rare diseases. With this latest investment, LG Technology Ventures' cumulative funding in biotech startups is estimated to have surpassed $50 million. The move aligns with LG's strategic emphasis on 'ABC' industries ― artificial intelligence, bio and clean tech ― as future growth engines. The conglomerate is focusing on creating cross-sector synergies by integrating advanced technologies with health care and sustainability-driven ventures. The group's Chair Koo Kwang-mo underscored the importance of AI and biotechnology in his New Year's address, saying, 'We are striving for a future where loved ones can live longer, healthier lives through breakthrough therapies.' In February, LG made a follow-up investment in ADARx Pharmaceuticals, a San Diego-based company developing first-in-class treatments for rare metabolic diseases through appetite suppression. LG has also invested in several other biohealth innovators, including: Aetion, Eko Health and Accellex. To strengthen its research and development capabilities, LG is increasingly integrating AI with biotechnology. Earlier this month, LG AI Research, the artificial intelligence arm of LG Group, unveiled Exaone Pass 2.0, an AI diagnostic model capable of identifying cancer in under one minute.

LG AI Research taps machine learning experts as new heads
LG AI Research taps machine learning experts as new heads

Korea Herald

time21-07-2025

  • Korea Herald

LG AI Research taps machine learning experts as new heads

LG AI Research appointed Lee Hong-lak, vice president and chief scientist of AI, and Lim Woo-hyung, a senior researcher leading its Data Intelligence Lab, as the institute's new co-heads of research on Monday. The appointments follow the departure of former head Bae Kyung-hoon, who left the post after being appointed as Minister of Science and ICT in June. According to LG, Lee is a globally recognized scholar in machine learning and deep learning. Named among the world's top 10 AI researchers, he also serves as a professor of computer science and engineering at the University of Michigan. Lee will lead LG's Global AI Center in Ann Arbor, Michigan, focusing on next-generation AI technologies and global recruitment, LG said. "Lee is expected to help integrate cutting-edge AI advancements into LG's research efforts while identifying top-tier AI talent worldwide," LG said. Joining him as co-head is Lim, an expert in machine learning and speech recognition. Lim has led applied AI research using LG's hyperscale AI model, Exaone, contributing to real-world problem-solving across LG affiliates and industries, LG said. "Lim will oversee the overall operation of the institute in Korea and expand Exaone-based AI services across LG businesses," the company added.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store